Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine plus methylprednisolone for severe acute alcoholic hepatitis
2023-510163-35-00Phase 3Authorised
- Sponsor
- Bioaraba
- Start
- Jan 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of acetylcysteine and methylprednisolone in alcoholic hepatitis (AH), sponsored by Bioaraba. Primary endpoint: 1-month mortality. Planned start Jan 2025; status: authorised.
02
Drugs
acetylcysteinemethylprednisolone
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on 2023-510163-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510163-35-00.